A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

NCT07028073 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
Acute Myeloid Leukemia With T(16;16)(P13;Q22)
KIT Gene Mutation
Avapritinib

Interventions

DRUG: Group A (FIT): Avapritinib + IA regimen
DRUG: Group B (UNFIT): Avapritinib + VA regimen

Sponsor

The First Affiliated Hospital of Soochow University